Scientific Collaborators - ArQule

The Ohio State University has been instrumental in the clinical development of ARQ 531, a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) that is in a phase 1 trial for B-cell malignancies refractory to other therapeutic options.

The National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) has been our partner from the beginning in studying the effect of miransertib (ARQ 092), a potent and selective inhibitor of protein kinase B (AKT), in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system. 

The University of Texas MD Anderson Cancer Center is spearheading the clinical development of ARQ 751, a next generation, highly potent and selective inhibitor of AKT. ARQ 751 is in phase 1 clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K) or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null.

The Ohio State University
National Institute of Health (NIH)
The University of Texas MD Anderson Cancer Center

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300